1,8-Cineol inhibits nuclear translocation of NF-κB p65 and NF-κB-dependent transcriptional activity  by Greiner, Johannes F.-W. et al.
Biochimica et Biophysica Acta 1833 (2013) 2866–2878
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcr1,8-Cineol inhibits nuclear translocation of NF-κB p65 and
NF-κB-dependent transcriptional activityJohannes F.-W. Greiner a, Janine Müller b, Marie-Theres Zeuner a, Stefan Hauser b, Thorsten Seidel c,1,
Christin Klenke d, Lena-Marie Grunwald a, Timo Schomann b, Darius Widera a, Holger Sudhoff d,2,
Barbara Kaltschmidt b,2, Christian Kaltschmidt a,⁎,2
a Department of Cell Biology, University of Bielefeld, D-33501 Bielefeld, Germany
b AG Molecular Neurobiology, University of Bielefeld, D-33501 Bielefeld, Germany
c Dynamic Cell Imaging, University of Bielefeld, D-33501 Bielefeld, Germany
d Klinik für Hals-, Nasen- und Ohrenheilkunde, Kopf- und Halschirurgie, Klinikum Bielefeld, D-33604 Bielefeld, Germany⁎ Corresponding author at: Department of Cell Bio
Universitätsstr. 25, D-33501 Bielefeld, Germany. Te
E-mail address: c.kaltschmidt@uni-bielefeld.de (C. Kal
1 Present address: Department of Plant Biology, Ca
Stanford, CA 94305, USA.
2 The authors have equal contributions.
0167-4889/$ – see front matter © 2013 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbamcr.2013.07.001a b s t r a c ta r t i c l e i n f oArticle history:
Received 14 June 2013
Accepted 8 July 2013
Available online 18 July 2013
Keywords:
1,8-Cineol
NF-κB
Human cell lines
PBMCs
Inﬂammation
Inﬂammatory diseasesNatural plant-derived products are commonly applied to treat a broad range of human diseases, including cancer
as well as chronic and acute airway inﬂammation. In this regard, the monoterpene oxide 1,8-cineol, the active
ingredient of the clinically approved drug Soledum®, is well-established for the therapy of airway diseases,
such as chronic sinusitis and bronchitis, chronic obstructive pulmonary disease and bronchial asthma. Although
clinical trials underline the beneﬁcial effects of 1,8-cineol in treating inﬂammatory diseases, the molecular mode
of action still remains unclear.
Here, we demonstrate for the ﬁrst time a 1,8-cineol-depending reduction of NF-κB-activity in human cell lines
U373 and HeLa upon stimulation using lipopolysaccharides (LPS). Immunocytochemistry further revealed a
reduced nuclear translocation of NF-κB p65, while qPCR and western blot analyses showed strongly attenuated
expression of NF-κB target genes. Treatment with 1,8-cineol further led to increased protein levels of IκBα in an
IKK-independent matter, while FRET-analyses showed restoring of LPS-associated loss of interaction between
NF-κB p65 and IκBα.We likewise observed reduced amounts of phosphorylated c-JunN-terminal kinase 1/2 pro-
tein in U373 cells after exposure to 1,8-cineol. In addition, 1,8-cineol led to decreased amount of nuclear NF-κB
p65 and reduction of its target gene IκBα at protein level in human peripheral blood mononuclear cells.
Our ﬁndings suggest a novel mode of action of 1,8-cineol through inhibition of nuclear NF-κB p65 translocation
via IκBα resulting in decreased levels of proinﬂammatoryNF-κB target genes andmay therefore broaden theﬁeld
of clinical application of this natural drug for treating inﬂammatory diseases.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Natural plant-derived products are widely applied to treat a broad
range of human diseases, particularly including cancer [1] as well as
chronic and acute airway inﬂammation [2,3]. In this regard, especially
terpenoids, like the monoterpene oxide 1,8-cineol (Fig. 1A), are of emi-
nent importance for the therapy of upper and lower airway diseases,
such as chronic sinusitis and bronchitis, chronic obstructive pulmonary
disease (COPD) and bronchial asthma [2,4–6].
Firstly described by Cloez in 1870, 1,8-cineol (or “eucalyptol”) is
known as the major constituent of the essential oil of Eucalyptuslogy, University of Bielefeld,
l.: +49 521 106 5625.
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ights reserved.globulus leafs [7], while later studies also demonstrated the presence
of 1,8-cineol in other plant species, such as rosemary [8] and Psidium
pohlianum [9]. Besides its isolation from E. globulus oil by fractional
distillation, 1,8-cineol can also be synthesized by isomerization of
α-terpineol [10].
Interestingly, in addition to its utility in treating bronchitis and
sinusitis [3,4], 1,8-cineol is also known to exhibit antinociceptive
properties. As described by Santos and colleagues in 2000, 1,8-
cineol showed an antinociceptive effect in male Swiss mice and
Wistar rats, thereby indicating a potential calmative action on the
central nervous system [11]. Moreover, the orally administered essen-
tial oil of Croton nepetaefolius, which contains 31.5% 1,8-cineol, signiﬁ-
cantly increased the latency of mice in an hot-plate test. In addition,
paw licking was signiﬁcantly reduced in the second phase of a formalin
test, underlining the antinociceptive effect [12]. 1,8-Cineol is also well-
known to exhibit direct protective effectswithin the rat andmurine sys-
tem, as in the case of ethanol-induced gastric mucosal damage [13] and
liver failure in an in vivomodel of endotoxemic shock [14].
Fig. 1. 1,8-cineol reduces the activity of NF-κB in human U373 cells in a pGreenFire1TM-NF-κB-Puro reporter gene assay. A. Structural formula of the monoterpene oxide 1,8-cineol
(molecular formula C10H18O). B. Schematic view on pGreenFire1TM-NF-κB-Puro-vector containing NF-κB response elements, a minimal CMV promotor as well as GFP and ﬁreﬂy
luciferase cassettes, which served as reporter gene construct to determine the NF-κB-activity. C. Confocal laser scanning microscopy revealed decreased amount of GFP-expressing
(pGreenFire1TM-NF-κB-Puro-vector-transfected) U373 cells in the cineol-treated approach (4.3% ± 2, lower panels) in comparison to non-treated control (12.5 ± 1.4, upper panels).
D. Transfected U373 showed signiﬁcantly decreased levels of luciferase activity, when exposed to 1,8-cineol. Merged data from biological triplicate, **p b 0.01 was considered signiﬁcant
(paired t-test, two-tailed, conﬁdence interval: 95%).
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1,8-cineol to inﬂammation, Santos and coworkers not only demonstrat-
ed an antinociceptive, but also an anti-inﬂammatory effect in bothmice
and rats [11]. Moreover, in 2004 the same group described a reduced
colonic damage in rats on acute trinitrobenzene sulfonic acid (TNBS)-
induced colitis, further conﬁrming the anti-inﬂammatory action of
1,8-cineol [15]. Likewise, Inoue et al. demonstrated a partial prevention
of allergic airway inﬂammation in a murine model of allergic asthma
induced by house dust mites [16]. Besides its properly characterized
direct anti-bacterial activity [17,18], 1,8-cineol was impressively
shown to reduce inﬂammation in clinical trials. In a double-blind
placebo-controlled trial with thirty-two patients, Juergens and co-
workers evidenced an anti-inﬂammatory activity of 1,8-cineol in
steroid-dependent bronchial asthma. In particular, twelve of 16 cineol
patients achieved a reduction of oral steroids, while only four out of
16 placebos led to signiﬁcant changes in steroid reduction [2]. More-
over, concomitant therapy with cineol was shown to reduce exacerba-
tions as well as dyspnea and improve lung function in a placebo-
controlled double-blind trial with 242 COPD patients [6].
Although these clinical trials and medical applications of 1,8-cineol
as a drug in therapy of inﬂammatory diseases are highly promising,
the detailed mode of action of 1,8-cineol still remains unknown.
Suggesting a mechanism of action by cytokine inhibition, Juergens and
colleagues demonstrated a signiﬁcantly inhibited production of TNF-α
and IL-1β human monocytes after treatment with 1,8-cineol in vitro
[19]. This is in accordance to in vivo data demonstrating reduced levelsof TNFα and IL-1β in airways of ovalbumin-challengedGuinea pig treat-
ed with 1,8-cineol inhalation [20].
Interestingly, several monoterpenoids are also known to direc-
tly inhibit the signaling via NF-κB (nuclear factor ‘kappa-light-
chain-enhancer’ of activated B cells) (reviewed in [21]), a key
regulator in the pathogenesis of inﬂammatory diseases.With regards
to these well-described inhibitory effects of monoterpenoids
[22–24], the aim of the present study was to determine a potential
effect of 1,8-cineol on NF-κB, thereby suggesting its possible mode
of action.
Here, we describe for the ﬁrst time a signiﬁcantly reduced activ-
ity of NF-κB after exposure to 1,8-cineol in the human cancer cell
lines U373 and HeLa, even after lipopolysacharid (LPS)-depending
stimulation of NF-κB-activity. Strongly reduced translocation of
NF-κB p65 into the nucleus was evidenced by immunocytochemis-
try, while qPCR and western blot analyses revealed decreased gene
expression of NF-κB target genes after their LPS-driven induction.
Increased protein levels of IκBα were observed in an IKK-
independent matter, accompanied by restoring of LPS-associated
impairment of interaction between NF-κB p65 and IκBα shown by
FRET-analyses. 1,8-Cineol was also found to reduce protein amounts
of phosphorylated c-Jun N-terminal kinase 1/2 in U373 cells in compar-
ison to LPS-treated cells. We additionally observed 1,8-cineol-induced
decrease of nuclear NF-κB p65 localization and reduction of its target
gene IκBα at protein level in human peripheral blood mononuclear
cells.
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hibition of nuclear NF-κB p65 translocation via IκBα, thereby likely
broadening its uses in the treatment of inﬂammatory diseases.
2. Materials and methods
2.1. Materials
1,8-Cineol was used from Soledum® capsules (Klosterfrau Healthcare
Group, Cassella-med GmbH & Co. KG, Cologne, Germany). Native ex-
tract (0.6 mg/μl 600 mg/ml 1,8-cineol) was stored at 4 °C, while
stock solution was prepared by solving native extract in ethanol
(100 mg/ml) followed by ﬁnal diluting with DMEM High Glucose
(Biochrom, Berlin, Germany; 1 mg/ml).
2.2. Cell culture
Human U373 glioblastoma and human HeLa cells were cultured
in a humidiﬁed incubator (Binder, Tuttlingen, Germany) at 37 °C
and 5% CO2 in tissue culture dish 100 (TPP Techno Plastic Products,
Trasadingen, Austria) and DMEM High Glucose (Biochrom) contain-
ing 200 mM L-Glutamine (Sigma-Aldrich, Taufkirchen, Germany),
Amphotericin B (1 ml (0.25 mg)/100 ml; PAA, Pasching, Austria),
and Penicillin/Streptomycin (1 ml (2 mg)/100 ml; PAA) and 10%
Fetal calf serum (lot:126 K3398, Sigma-Aldrich). Hereinafter, the de-
scribed composition of medium is referred to as “standard medium”.
Medium change was performed every two to three days, while passag-
ingwas done after at least oneweek. For passaging, adherently growing
cells were digested using trypsin (Trypsin-EDTA, 0.5 mg/mL; PAA) for
10 min at 37 °C followed by harvesting via centrifugation and replating
in standard medium.
2.3. Isolation of peripheral blood mononuclear cells (PBMCs) from human
whole blood via density gradient centrifugation
PBMCs were isolated using Easycoll (Ficoll, Biochrom AG, Berlin, Ger-
many) by density gradient centrifugation according to manufacturer's
guidelines (Biochrom AG). Brieﬂy, human whole blood samples were
obtained from healthy donors after informed consent according to local
and international guidelines (Bezirksregierung Detmold/Münster). He-
parinized human whole blood was mixed 1:2 with PBS in a 50 ml
Tube (Greiner Bio-One GmbH, Frickenhausen, Germany) and 28 ml
were layered on top of 12 ml Easycoll followed by centrifugation for
30 min at 400 × g and RT. PBMCs were located in a clearly discernible
white, cloudy layer in the interphase between the Easycoll-separation
solution (lower phase) and serum (supernatant), while erythrocytes
and granulocytes remained within the pellet. Collection of PBMCs by
pipetting into a 50 ml Tube (Greiner) was followed by twice times
washing using PBS. Isolated PBMCswere resuspended in RPMI medium
(PAA, Pasching, Austria) with 10% human serum gained from superna-
tant of density gradient centrifugation procedure and further cultivated
in Tissue Culture Dish (Waldeck GmbH & Co KG, Münster, Germany) at
37 °C and 5% CO2 using a humidiﬁed incubator (Binder, Tuttlingen,
Germany).
2.4. Transient transfection of human cell lines and gene reporter assays
For transient transfection, U373- and HeLa cells cultivated in
standard medium as described above were treated with trypsin
(Trypsin-EDTA, 0.5 mg/mL; PAA) for 10 min followed by harvesting
via centrifugation. Afterwards, 3 × 106 cells were transfected with
pGreenFire1™-NF-κB-Puro-vector (1 μg, System Biosciences), NF-
AT luciferase reporter vector (Addgene Plasmid No. 10959, [25]) or
cotransfected with TK(NF-κB)6LUC vector (1 μg, [26]) and pRLcmv
vector or pRL-TK vector (2 μg, Promega Corporation, Mannheim,
Germany), using the Nucleofector II device (Lonza Group, Basel,Switzerland) and the rat NSC Nucleofector Kit (Lonza Group) according
to manufacturer's guidelines. FPred (Lonza Group) or pmaxGFP (Lonza
Group) served as transfection controls. Transiently transfected cells
were cultivated in standard medium for 24 h, followed by addition of
respective combinations of 1,8-cineol (Klosterfrau Healthcare Group),
LPS (100 ng/ml, rough strains from Salmonella enterica Re 595, cat.
no. L9764, Sigma-Adrich) and NF-κB-inhibiting factors (1 μM dexa-
methasone (Sigma-Aldrich), 2 μM insulin (Sigma-Aldrich), 500 μM
3-isobutyl-1-methylxanthine (Sigma-Aldrich) and 200 μM indomethacin
(Sigma-Aldrich)). Analysis of gene reporter activity was performed 24 h
after exposure to respective substances by confocal laser scanning
microscopy (LSM 510 with ZEN software, Carl Zeiss, Jena, Germany)
or measurement of luciferase activity. All assays were performed at
least as triplicates.
For assessment of luciferase activity, transfected cells were harvested
using Cell scrapper S (TPP) and lysed in 1× Passive Lysis buffer (Promega
Corporation). Dual-Luciferase® Reporter Assay System (Promega
Corporation, cat. no. E1960) was applied for measuring luciferase ac-
tivity according to manufacturer's guidelines, while Graph Pad Prism
software (GraphPad Software, La Jolla, CA, USA) was applied for sub-
sequent statistical analysis. In the case of dual luciferase reporter
assay, signals were normalized as a ratio of ﬁreﬂy luciferase activity
to Renilla luciferase activity.
Optimal working concentration of 1,8-cineol was investigated with-
in preliminary assays, leading to the application of 10−4 M 1,8-cineol
within all assays (Fig. S1).
2.5. Proliferation assay
To investigate the effects of cineol on proliferation of HeLa and
U373 cells, 1 × 104 cells were plated in standard medium comprising
respective concentrations (10−3 M–10−9 M) of 1,8-cineol (Klosterfrau
Healthcare Group) and cultivated as described above. Cell numbers
were determined after 8 days via trypsinisation (Trypsin-EDTA,
0.5 mg/mL; PAA) and subsequent cell number determination using
the Cellometer Auto T4 device (Peqlab Biotechnology, Erlangen,
Germany). Proliferation assay was performed as biological triplicate,
statistical analysis was performed using Graph Pad Prism software
(GraphPad Software).
2.6. Immunocytochemistry
For immunocytochemistry, HeLa cells, U373 cells and PBMCs were
cultivated under exposure to respective combinations of 1,8-cineol
(10−4 M, (Klosterfrau Healthcare Group) and LPS (100 ng/ml, rough
strains from S. enterica Re 595, cat. no. L9764, Sigma-Adrich) for 24 h.
Afterwards, cells were ﬁxed using phosphate buffered 4% PFA and
permeabilized with 0.02% Triton X-100 for 30 min at RT. Blocking was
performed using 5% of appropriate normal serum, followed by addition
of the primary anti p65-antibody (NF-κB-p65 SC-372, Santa Cruz Bio-
technology) for 2 h at RT. Secondary ﬂuorochrome-conjugated anti-
body (goat anti rabbit conjugated with Alexa 555; Molecular Probes,
Göttingen, Germany) was subsequently incubated for 1 h at RT. For nu-
clear counterstaining, SYTOX green (1:20,000, Molecular Probes,
Göttingen, Germany) was applied after RNAse treatment (N500 U/mL,
Fermentas), while ﬂuorescence imaging was performed using confocal
laser scanning microscopy (LSM 510, Carl Zeiss). Quantiﬁcation was
performed using Image J [27] by deﬁning a region of interest according
to the localization of the respective nucleus and measurement of ﬂuo-
rescence intensity in the same region.
2.7. Real time PCR
Total RNA was isolated from U373 cells using RNeasy Mini Kit
(QIAGEN, Hilden, Germany) followed by cDNA synthesis by First Strand
cDNA Synthesis Kit (Fermentas, St. Leon-Rot, Germany) according to
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using Platinum SYBR Green qPCR Super-Mix UDG (Invitrogen, Life Tech-
nologies GmbH, Darmstadt, Germany) according to manufacturer's
guidelines and assayed with a Rotor Gene 6000 (QIAGEN, Hilden,
Germany). Primer sequenceswere CAGAGGGCCTGTACCTCATC (forward)
and GGAAGACCCCTCCCAGATAG (reverse) for TNFα, GTGCAGTTTTGCCA
AGGAGT (forward) and CTCTGCACCCAGTTTTCCTT (reverse) for IL-8 as
wells as AGACCTGGCCTTCCTCAACT (forward) and GTCTCGGAGCTCA
GGATCAC (reverse) for IκBα.
2.8. Western blot
0 min, 10 min, 30 min, 60 min, 90 min, 120 min and 24 h after
exposure to respective combinations of 1,8-cineol (10−4, Klosterfrau
Healthcare Group) and LPS (100 ng/ml, rough strains from S. enterica
Re 595, cat. no. L9764, Sigma-Aldrich), cells were lysed on ice using
200 μl of lysis buffer (10 mM Tris, 1% SDS, 3 mM EDTA) and homog-
enized with ultrasonics. After determination of protein concentra-
tion with BCA Protein Assay Kit (Thermo Fisher Scientiﬁc Inc.,
Rockford, USA) the protein amounts of each sample were adjusted
to 20 ng/ml and mixed with 5 × loading buffer followed by heating
at 94 °C for 5 min. Samples were subjected to electrophoresis on
10% denaturing SDS polyacrylamide gels and transferred with a
semi-dry blotter to a nitrocellulose membrane (Carl Roth GmbH,
Karlsruhe, Germany). Blocking of the blots using 5% milk powder (Carl
Roth GmbH, Karlsruhe, Germany) in PBS was followed by incubation
with the ﬁrst antibody against IκBα (Enzo Life Sciences, Lörrach,
Germany), phospho-IκBα (Cell Signaling Technology, Cambridge,
UK), JNK1/JNK2 (BD Pharmingen), phospho-JNK1/2 (Invitrogen),
ERK (Cell Signaling Technology) and phospho-ERK (Cell Signaling
Technology) overnight. HRP-linked secondary antibody was ap-
plied for 1 h at RT. Visualizationwas performed via enhanced chemilu-
minescence, while GAPDH (Santa Cruz Biotechnology, Heidelberg,
Germany) served as loading control.
2.9. FRET-measurements
U373-cells cultivated in standard medium as described above
were treated with trypsin (Trypsin-EDTA, 0.5 mg/mL; PAA) for
10 min followed by harvesting via centrifugation. 8 × 105 cells
were cotransfected with NF-κB p65-EYFP and IκBα-mCherry [28]
using TurboFect Transfection Reagent (Thermo Fisher Scientiﬁc
Inc) according to manufacturer's guidelines. For determination of
correction factors during the analyses, single transfections were
performed using NF-κB p65-EYFP, IκBα-mCherry and CMV-EYFP-
mCherry [28]. Transiently transfected cells were cultivated in standard
medium for 24 h, followed by addition of respective combinations of
1,8-cineol (Klosterfrau Healthcare Group) and LPS (100 ng/ml, rough
strains from S. enterica Re 595, cat. no. L9764, Sigma-Adrich).
Analyses were performed by confocal laser scanning microscopy
applying a Zeiss LSM780 imaging system. The donor EYFP was de-
tected by PMT1 in the range of 499–550 nm and excited with the
488 nm laser line of an argonion-laser, in parallel the FRET-signal
was recorded with PMT2 in the range of 569–650 nm. The same
range of PMT2 was additionally applied in another sequence for
detecting the acceptor emission with excitation at 561 nm by a
DPSS-laser. Sequences were recorded line by line and the main
beam splitter MBS488/561 was applied. A water-immersion LD-
objective was used (Zeiss LCI Plan-Neoﬂuar 63×/1.3 Imm. Korr. DIC
M27), pixel dwell time has been 6.3 μs, image size 512 × 512 pixel
and intensity resolution 12-bit/pixel. Frames were obtained every
ﬁve minutes for a time span of 120 min at three positions for each
condition. Data was evaluated based on single cell ROIs of ﬁve cells
per frame.
FRET-calculation and required determination of correction factors
were performed as described before [28].3. Results
3.1. Exposure to 1,8-cineol leads to signiﬁcantly decreased levels of
NF-κB-activity in human U373 cells in a pGreenFire1TM-NF-κB-Puro
reporter gene assay
Potential effects of 1,8-cineol on the NF-κB-activity in human U373
cells were investigated by transient transfection of a pGreenFire1TM-
NF-κB-Puro-vector containing a GFP and luciferase reporter cassette
(Fig. 1B). Confocal laser scanningmicroscopy revealed successful trans-
fection of U373 cells, as indicated by strong expression of FPred control
vector (Fig. 1C, left panels). To initially determine the activity of NF-κB,
the percentage of GFP-positive to FPred-expressing cells was assessed
leading to a percentage of 12.5% ± 1.4 GFP-expressing cells in the
non-treated control-approach (Fig. 1C, upper panels). Notably, only
4.3% ± 2.6 cineol-treated U373 showed expression of GFP (Fig. 1C,
lower panels), thereby indicating a decrease of NF-κB-activity. On ac-
count of its higher sensitivity, luciferase activity was subsequently de-
termined in both cineol- and non-treated U373 cells. Here, signiﬁcant
reduction of luciferase activity was observed in the cineol approach
(Fig. 1D).
3.2. 1,8-Cineol signiﬁcantly reduces the NF-κB-activity in human U373 and
HeLa cells
With regards to the initially demonstrated reduction of NF-κB-
activity by 1,8-cineol in U373 cells, we investigated this matter in
more detail using U373 and HeLa cells transiently transfected with
a dual NF-κB-reporter system, which consisted of a TK(NF-κB)6LUC
vector (ﬁreﬂy luciferase) and Renilla luciferase expression vector
under the control of a constitutive promotor (Fig. 2A). Renilla lucifer-
ase served for normalization of the ﬁreﬂy luciferase activity of the
TK(NF-κB)6LUC-reporter construct. Thereby allowing a more pro-
found analyses of the NF-κB-activity, luciferase activity was mea-
sured in non-treated and cineol-exposed U373 and HeLa cells after
co-transfection of TK(NF-κB)6LUC vector and Renilla luciferase vec-
tor. As shown in Fig. 3B, signiﬁcantly reduced levels of luciferase ac-
tivity were observable in cineol-treated approaches in both U373
(Fig. 2B, left panel) and HeLa cells (Fig. 2B, right panel). Notably,
compared to standard NF-κB-inhibiting factors (including dexa-
methasone, 3-isobutyl-1-methylxanthine and indomethacin), 1,8-
cineol-treatment led to a similar level of reduced NF-κB-activity in
U373 cells (Fig. 2B, left panel), while an even stronger reduction of
NF-κB-activity was observable in HeLa cells (Fig. 2B, right panel).
3.3. 1,8-Cineol-treatment impairs proliferation capability of U373 andHeLa
cells
Given the signiﬁcantly reduced NF-κB-activity in 1,8-cineol-treated
U373 and HeLa cells, we additionally investigated potential effects of
1,8-cineol on proliferation. When exposed to concentrations of 10−4 M,
10−5 M, 9 × 10−6, 7 × 10−6, 5 × 10−6 M, 10−6 M, 10−7 M, 10−8 M
and 10−9 M 1,8-cineol for 8 days, U373 cells showed signiﬁcantly
decreased cell numbers (Fig. 3A), while no signiﬁcant differences were
observed in cells treated with 10−3 M and 10−6 M cineol. Respective
concentrations of 1,8-cineol led to even more signiﬁcant decreases
in total cells numbers of Hela cells after 8 days of culture, except
for 10−7 M 1,8 cineol (Fig. 3B).
3.4. 1,8-Cineol signiﬁcantly attenuates the NF-κB-activity after LPS-induced
stimulation accompanied by strongly reduced nuclear translocation of
NF-κB p65
Regarding the use of 1,8-cineol as an anti-inﬂammatory drug, we in-
vestigated its potential effects after LPS-induced activation of NF-κB in
U373 and HeLa cells. As shown in Fig. 4A, exposure to LPS led to highly
Fig. 2. A dual NF-κB-reporter system revealed a 1,8-cineol-dependent reduction of NF-κB-activity in human U373 and HeLa cells without strongly affecting proliferation capabilities. A. Schematic
view on dual NF-κB-reporter system containing TK(NF-κB)6LUC vector for detecting NF-κB-activity and a vector constitutively expressing Renilla luciferase for normalization. B. Signiﬁ-
cantly reduced levels of luciferase activity were observed in co-transfected U373- (left panel) and HeLa cells (right panel) after cineol-treatment in comparison to untreated control.
Merged data from biological triplicate. **p b 0.01 was considered signiﬁcant (paired t-test, two-tailed, conﬁdence interval: 95%). C. Compared to standard NF-κB-inhibiting factors (in-
cluding dexamethasone, 3-isobutyl-1-methylxanthine and indomethacin), 1,8-cineol-treatment led to a similar (left panel) or even stronger (right panel) reduced NF-κB-activity in
co-transfected U373- (left panel) and HeLa cells (right panel). *p b 0.05, **p b 0.01, ***p b 0.001 were considered signiﬁcant (unpaired t-test, two-tailed, conﬁdence interval: 95%).
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cantly reduced luciferase activity was observed when U373 cells were
exposed to both LPS and 1,8-cineol. Likewise, LPS-treated HeLa cells
revealed increased levels of luciferase activity, which signiﬁcantly
decreased by cineol-treatment (Fig. 4B, left panel). Moreover, confocal
scanningmicroscopy of pGreenFire1TM-NF-κB-Puro-vector transfected
HeLa cells showed an increased amount of GFP-positive cells (36.3% ±
10.1) compared to control (17.0% ± 3.0). Importantly, the number of
GFP-expressing cells declined even below control level, when HeLacells were exposed to both LPS and 1,8-cineol (9.3% ± 1.0, Fig. 4B,
right panel).
Considering the reduced activity of NF-κB after exposure to 1,8-
cineol, even after LPS-treatment, we further determined the localiza-
tion of p65-protein, a major subunit of NF-κB [29], via immunocyto-
chemistry. In comparison to the control approach (Fig. 4C, right
panel, arrowheads), we observed translocation of p65 into the nucle-
us of HeLa cells after LPS-stimulation (Fig. 4C, middle panel, arrows).
Importantly, HeLa cells treated with LPS and 1,8-cineol showed highly
Fig. 3. 1,8-cineol-treatment impaired proliferation capability of U373 and HeLa cells.A. Signiﬁcantly decreased cell numberswere observed in U373 cells after exposure to respective concen-
trations of 1,8-cineol for 8 days, except for 10−3 M and 10−6 M cineol. B. 1,8-cineol-treatment led to signiﬁcant decreases in total cells numbers of Hela cells after 8 days of culture, except
for 10−7 M 1,8 cineol. *p b 0.05, **p b 0.01 and ***p b 0.001 (unpaired t-test, one-tailed, conﬁdence interval: 95%) were considered signiﬁcant.
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translocation of p65 into the nucleus (Fig. 4C, right panel, arrowheads).
Quantiﬁcation of data gained from three independent experiments ver-
iﬁed our observations by showing signiﬁcantly increased levels of nu-
clear p65-protein after exposure to LPS, while cineol-treatment led to
signiﬁcantly reduced levels (Fig. 4E).
3.5. Decreased nuclear translocation of NF-κB p65 in 1,8-cineol-treated
U373 cells is associated with reduced expression of NF-κB target genes
Substantiating our ﬁndings gained using HeLa cells, representa-
tive immunocytochemical analysis demonstrated localization of
p65 within the nucleus of U373 cells after LPS-stimulation (Fig. 5A,
middle panel, arrows), while exposure to LPS and 1,8-cineol led to
decreased levels of nuclear p65 (Fig. 5A, right panel, arrowheads)
comparable to control (Fig. 5A, left panel, arrowheads). Notably, at
least some U373 cells showed low amounts of nuclear p65 even
after exposure to LPS (Fig. 6A, middle panel, arrowheads). Importantly,
further quantiﬁcation depicted signiﬁcantly increased amount of
nuclear p65 in response to LPS-stimulation, while signiﬁcant reduction
of nuclear p65 was observed in cineol-treated U373 cells (Fig. 7B).
In order to investigate a potential correlation between nuclear trans-
location of NF-κB p65 and potential alterations in expression of NF-κB
target genes, we further investigated expression levels of TNFα and IL-
8 via real time PCR. Here, LPS-treated U373 cells showed increased
gene expression levels of TNFα and IL-8 in comparison to control
(Fig. 5B), while co-treatment with 1,8-cineol led to strongly attenuated
gene expression.Western blot analyses demonstrated an increased pro-
tein amount of NF-κB target gene IκBα after 24 h in LPS-treated U373
cells, which was strongly reduced by co-treatment with 1,8-cineol
(Fig. 5C).
3.6. Treatmentwith 1,8-cineol leads to increased levels of IκBα in U373 cells
in an IκB kinase-independent matter
With regard to the strongly reduced levels of NF-κB target genes, we
determined the potential inﬂuence of 1,8-cineol on IκBα. Western blot
analyses over a short range of time (0–120 min) revealed highly
decreasing protein amounts of IκBα in LPS-treated U373 cells in com-
parison to control (Fig. 5E, upper andmiddle panels, IκBα). On the con-
trary to the observationsmade in the LPS approach, the protein amount
of IκBαwas found to be increasing in U373 cells exposed to LPS and 1,8-cineol after 90 min (Fig. 5E, lower panels, IκBα). Since changes in IκBα-
protein amount are broadly known to be associatedwith its proteasomal
degradation mediated through IκB kinase (IKK)-dependent phosphory-
lation, we investigated phosphorylation of IκBα using western blot.
After 10 min of LPS-treatment, U373 cells showed increased amounts
of phosphorylated IκBα (Fig. 5E, middle panels, pIκBα). We observed
increased amounts of phosphorylated IκBα after 10 min also in U373
cells treated with LPS and 1,8-cineol (Fig. 5E, lower panels, pIκBα), a
ﬁnding suggesting that 1,8-cineol may lead to increased IκBα-protein
amounts in an IKK-independent matter. Remarkably, the protein
amounts of unphosphorylated and phosphorylated IκBα were likewise
highly increased after 120 min in LPS and 1,8-cineol treated U373 cells
compared to the LPS-approach.3.7. LPS-induced loss of interaction between NF-κB p65 and IκBα is restored
by 1,8-cineol
Considering the reduced nuclear translocation of NF-κB p65 and de-
creased levels of NF-κB target genes, the potential inﬂuence of 1,8-
cineol on the interaction between NF-κB p65 and IκBαwas investigated
using Förster resonance energy transfer (FRET) analyses.We transiently
transfected U373 cells with vectors containing a NF-κB p65 linked to
EYFP as well as a mCherry-coupled IκBα (Fig. 6A). Transfected cells
were treated with LPS or LPS and 1,8-cineol and analyzed for 120 min,
while untreated cells were used as control. As representatively shown
for one cell in Fig. 6B, we observed no decline in FRET efﬁciency in the
control approach (left upper panel). Importantly, LPS-treatment led to
strongly impaired FRET efﬁciency (Fig. 6B, right upper panel), which
was restored in U373 cells treated with LPS and 1,8-cineol (Fig. 6B, left
lower panel). In accordance to the increasing IκBα protein amounts ob-
served during exposure to LPS and 1,8-cineol using western blot ana-
lyzes, FRET efﬁciency was particularly found to decrease in the ﬁrst
place up to 60 min, and increased afterwards up to control level. Ana-
lyzing slopes of regression lines of graphs depicting FRET efﬁciency of
representative cells in three different measurement areas per approach
veriﬁed our observations by showing signiﬁcant reduction of FRET efﬁ-
ciency over time in LPS-treated cells compared to control. Treatment
with LPS and cineol led to signiﬁcantly increased slope of FRET efﬁciency
within the complete timespan (Fig. 6B, right lower panel), suggesting a
restored interaction between IκBα and NF-κB p65 compared to the LPS-
approach.
Fig. 4.1,8-cineol signiﬁcantly attenuated the NF-κB-activity after LPS-induced stimulation accompanied by strongly reduced nuclear translocation of NF-κB p65. A. LPS-treatedU373 cells showed
highly increased levels of luciferase activity, which signiﬁcantly decreased when U373 cells were exposed to both LPS and 1,8-cineol. Representative data from biological triplicate.
Luciferase activity was normalized by detection of constitutively expressed Renilla luciferase. ***p b 0.001 was considered signiﬁcant (unpaired t-test, two-tailed, conﬁdence interval:
95%). B. Luciferase activity signiﬁcantly increased in HeLa cells after LPS-treatment, while exposure to LPS and 1,8-cineol led to signiﬁcantly reduced levels of luciferase activity (left
panel). Representative data from biological triplicate. ***p b 0.001 was considered signiﬁcant (unpaired t-test, two-tailed, conﬁdence interval: 95%). Confocal scanning microscopy of
pGreenFire1TM-NF-κB-Puro-vector-transfected HeLa cells demonstrated an increased amount of GFP-positive cells (36.3% ± 10.1) after LPS-treatment compared to control approach
(17.0% ± 3.0). Importantly, the number of GFP-expressing cells declined (9.3% ± 1.0), when HeLa cells were exposed to both LPS and 1,8-cineol (right panel). C. Representative
immunocytochemical analysis showing localization of p65 within the nucleus of HeLa cells after LPS-stimulation (middle panel, arrows), while exposure to LPS and 1,8-cineol led
to decreased levels of nuclear p65 (lower panel, arrowheads). D. Quantiﬁcation of immunocytochemical analyses from three independent experiments depicted signiﬁcantly increased
amount of nuclear p65 in LPS-stimulated HeLa cells, while cineol-treatment led to signiﬁcant reduction of nuclear p65. ***p b 0.001 was considered signiﬁcant (unpaired t-test, two-
tailed, conﬁdence interval: 95%).
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associated with reduced amounts of phosphorylated c-Jun N-terminal
kinase 1/2 protein
To further investigate the potential inﬂuence of 1,8-cineol on
IκBα, we analyzed IκBα-expression on mRNA-level using real time
PCR. U373-cells treated with 1,8-cineol and LPS as well as LPS alone
revealed no changes of IκBα-expression above threshold level
(Fig. 7A), suggesting that glucocorticoid signaling is not likely to beinvolved in the 1,8-cineol-associated decrease of NF-κB target gene
expression.
Extending our investigations on potential effects of 1,8-cineol on the
Mitogen-activated protein 1 kinase (MAP1K)-pathways, we assessed
phosphorylation of c-Jun N-terminal kinase 1/2 (JNK1/2) as well as extra-
cellular signal-regulated kinase (ERK) via western blot analyses. LPS and
1,8-cineol treated U373-cells showed highly reduced amounts of phos-
phorylated JNK1/2 after 10 min in comparison to cells exposed to LPS
only (Fig. 7B). Remarkably, the total protein amounts of JNK1/2 were
Fig. 5. Treatment with 1,8-cineol resulted in signiﬁcantly decreased nuclear translocation of NF-κB p65 in U373 cells and reduced expression of NF-κB target genes, while protein amount of IκBα
was increased.A. Representative immunocytochemical analysis showing translocation of p65 into the nucleus of U373 cells after LPS-stimulation (middle panel, arrows), while exposure to
LPS and 1,8-cineol led to decreased levels of nuclear p65 (right panel, arrowheads). B. Quantiﬁcation of immunocytochemical analyses from three independent experiments depicted sig-
niﬁcantly increased amount of nuclear p65 in LPS-stimulated U373 cells, while cineol-treatment led to signiﬁcant reduction of nuclear p65. *p b 0.05 and ***p b 0.001 were considered
signiﬁcant (unpaired t-test, two-tailed, conﬁdence interval: 95%). C. Real time PCR analyses revealed elevated gene expression levels of NF-κB target genes TNFα and IL-8 after 24 h in
LPS-treated U373 cells, which were strongly reduced by co-treatment with 1,8-cineol. b.d.l.: below detection limit. D. Protein amounts of NF-κB target gene Iκbα were analyzed after
24 h via western blot revealing an LPS-induced increase, which was attenuated by 1,8-cineol. E. Western blot analyses over a short range of time (0-120 min) showed highly decreasing
protein amounts of IκBα in LPS-treated U373 cells, but increasing amounts in U373 cells exposed to LPS and 1,8-cineol. Protein amount of phosphorylated IκBα (p IκBα) were augmented
after 10 min in LPS as well as in LPS and 1,8-cineol treated U373 cells. U373 cells treated with LPS and 1,8-cineol showed highly increased amounts of unphosphorylated and phosphor-
ylated IκBα after 120 min.
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treated U373 cells compared to the LPS-approach. On the contrary,
amounts of ERK or phosphorylated ERK were not affected by 1,8-cineol
(Fig. 7C).
We also observed no signiﬁcant changes in NF-AT-activity in U373
cells treated with LPS and 1,8-cineol compared to LPS- and control-
approaches using a NF-AT- luciferase reporter gene assay [25] (Fig. S2).
3.9. 1,8-Cineol strongly decreases nuclear NF-κB p65 and protein amount of
its target gene IκBα in human peripheral bloodmononuclear cells (PBMCs)
Substantiating the inhibitory effect of 1,8-cineol on NF-κB, we inves-
tigated its potential role in humanperipheral bloodmononuclear cells, awell-establishedmodel in terms of inﬂammatory diseases. Using immu-
nocytochemistry, a LPS-induced nuclear translocation of NF-κB p65was
observed in PBMCs (Fig. 8A,middle panels) in comparison to the control
approach (Fig. 8A, left panels). Treatment with LPS and 1,8-cineol
resulted in reduced nuclearNF-κB p65 (Fig. 8A, right panels). Respective
Western blots showed an increased amount of the NF-κB target gene
IκBα at protein level in LPS-treated PBMCs, which was strongly attenu-
ated in PBMS exposed to LPS and 1,8-cineol (Fig. 8B).
4. Discussion
This study describes for the ﬁrst time that 1,8-cineol, the active in-
gredient of the drug Soledum®, signiﬁcantly reduces the activity of
Fig. 6. Loss of interaction between NF-κB p65 and IκBα during LPS-treatment was restored by 1,8-cineol.A. Schematic viewof Förster resonance energy transfer (FRET) between EYFP linked to
NF-κB p65 andmCherry coupled to IκBα. B. FRET efﬁciency over time. RepresentativeU373 cells cotransfectedwith NF-κB p65-YFP and IκBα-mCherry showed no decline in FRET efﬁcien-
cy over time in the control approach, while LPS-treatment led to strongly impaired FRET efﬁciency, which was restored by 1,8-cineol. Slopes of regression lines of graphs depicting FRET
efﬁciency over time. Representative cells in three different measurement areas per approach showed signiﬁcantly reduced FRET efﬁciency in LPS-treated cells compared to control. Treat-
ment with LPS and cineol led to signiﬁcantly increased levels of FRET efﬁciency. **p b 0.01 was considered signiﬁcant (unpaired t-test, one-tailed, conﬁdence interval: 95%).
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Closely linked to a broad variety of inﬂammatory human diseases
(such as asthma, rheumatoid arthritis or septic shock), the transcrip-
tion factor NF-κB is well-described to be activated in response to
proinﬂammatory cytokines, viral infection or exposure to bacterial lipo-
polysaccharides [30–33]. Initiating a signaling cascade to activate NF-
κB, lipopolysaccharides bind to the TLR-4 (toll-like receptor-4) [34],
leading to recruitment of MyoD88 followed by phosphorylation of
IKKs, in turn leading to the phosphorylation, polyubiquitylation and
26S-proteasome-mediated degradation of IκBs. Hence IκBs mask the
nuclear translocation signal region (NLS) of NF-κB, this process is
followed by translocation of NF-κB into the nucleus, where downstream
genes are activated via binding to cognate κB-sites [30,31,35]). This is in
accordance to the here presented data, since we demonstrate reduced
protein amounts of IκBα, impaired interaction between IκBα and NF-κB p65, translocation of NF-κB p65 into the nucleus, the active binding
to κB-sites as well as an increased gene expression of NF-κB target
genes after exposure to bacterial LPS.
Most pro-inﬂammatory conditions are considered to activate NF-
κB in various cell types [36–42]. In the present study, we investigated
the molecular mechanism of the anti-inﬂammatory effect of 1,8-
cineol using the human cancer cell lines HeLa and U373 as well as pe-
ripheral blood mononuclear cells. Particularly PBMCs represent a
well-established and LPS-inducible model for investigating inﬂam-
matory diseases, as reported in terms of COPD [43] and asthma
[44]. Notably, HeLa- and U373 cell lines are commonly applied to
study NF-κB-depending inﬂammatory responses and signaling
in vitro [45–49], also providing a direct link to the molecular mode
of action. Regarding the LPS-induced stimulation of NF-κB, U373
cells have been shown to be LPS/sCD14-responsive and TLR4 expressing
[50,51], while HeLa cells express TLR4 [52,53] but seem to lack MD-2-
Fig. 7. 1,8-cineol-treatment did not affect expression of IκBα on mRNA level, but was associated with reduced amounts of phosphorylated c-Jun N-terminal kinase 1/2 protein. A. Real time PCR
analyses revealing no changes of IκBα-expression above threshold level. B. Protein amounts of c-Jun N-terminal kinase 1/2 (JNK1/2) as well as phosphorylated JNK1/2 (pJNK1/2) showed
increased amounts of pJNK1/2 (30 min, 60 min) in U373 cells treatedwith LPS and 1,8-cineol in comparison to cells exposed to LPS only. C. Protein amounts of extracellular signal-regulated
kinase (ERK) as well as phosphorylated ERK revealed no differences between U373 cells treated with LPS and 1,8-cineol and LPS only.
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signaling can also occur in MD-2 independent manner ([55], al-
though this matter is controversially discussed [56]. Since in our
hands, HeLa cells can activate NF-κB after LPS-treatment, we suggestFig. 8. 1,8-cineol decreased nuclear NF-κB p65 and protein amount of its target gene IκBα in human
calization of p65within the nucleus of LPS-stimulated PBMCs (middle panel), while decreased l
arrowheads). B. Western blot analyzes showed an increased amount of the NF-κB target genethat the initial signaling step including receptor dimerizationmay be
mediated by an alternative, unknown mechanism. Demonstrably,
Yin and coworkers reported aspirin-mediated prevention of NF-κB-
activation by inhibition of IKK-β in an in vitro model using HeLaperipheral blood mononuclear cells (PBMCs) A. Immunocytochemical analysis revealed lo-
evels of nuclear p65were observed in PBMCs treatedwith LPS and 1,8-cineol (lower panel,
Iκbα at protein level in LPS-treated PBMCs, which was strongly attenuated by 1,8-cineol.
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inﬂammatory responses [47]. Besides such NF-κB-inhibiting effects
of prominent drugs [47,57], a broad range of natural products like
sesquiterpene lactones [58], hypericin [59], Plagius ﬂosculosus ex-
tract [60], incensole acetate isolated from Boswellia resin [61],
plant extracts from Urtica dioica [62] or monoterpenoids [21,23,63]
are well-known to reduce NF-κB-activity. Interestingly, several of
said NF-κB-inhibiting monoterpenoids are already applied in
treating inﬂammation and cancer, as in the case of Aucubin [22,64],
Genipin [24,64], Perillyl alcohol [65] and α-Pinene [63]. Thereby,
monoterpenoids either inhibit IκB-degradation [22,24], transloca-
tion of the p65-protein [63] or change the DNA binding activity of
the translocated p65 [21,65].
Although closely related to the monoterpenoid Limonene, which is
inhibiting NF-κB by changing its DNA binding activity [65], 1,8-cineol
(also known as Limonen-1,8-monoxid) was reported to have no effects
on nuclearNF-κB in THP-1 cells [5]. However, even in 1998 Juergens and
colleagues evidenced a signiﬁcantly inhibited production of TNF-α and
IL-1β after treatmentwith 1,8-cineol in human bloodmonocytes in vitro
[19]. Moreover, the same group substantiated the role of 1,8-cineol as a
strong inhibitor of TNF-α and IL-1β in both humanmonocytes and lym-
phocytes [66], suggesting a link between the mode of action of 1,8-
cineol and NF-κB-inhibition. This putative mode of action was further
supported by two studies which demonstrated eucalyptol ameliorating
bacterial vaginosis and cerulein-induced acute pancreatitis by inhibition
of NF-κB activation in the mice system [67,68].
The present study extended these ﬁndings by depicting increasing
protein amounts of IκBα, restored interaction between IκBα and NF-κB
p65, a lack of p65-translocation into the nucleus, signiﬁcantly decreased
binding to κB-sites aswell as attenuated expression levels of NF-κB target
genes in response to 1,8-cineol-treatment after stimulationwith LPS. Our
data suggest IκBα as well as JNK as potential targets of 1,8-cineol (see
Fig. 9 for schematic overview), provided that JNK may act directly onFig. 9. Potential mode of action of 1,8-cineol. Schematic view on LPS-stimulated cell. 1,8-cineol in
JNK-dependent manner.NF-κB target gene expression via AP-1. Lack of IκBα-degradation seems
to be phosphorylation-independent, suggesting the potential involve-
ment of changed kinetics in an IKK-independent manner.
In addition to its well-described anti-inﬂammatory activity,
Moteki and colleagues demonstrated a 1,8-cineol-dependent induc-
tion of apoptosis in human leukemia Molt 4B and HL-60 cells [69].
Given these ﬁndings, we investigated the potential effects of 1,8-
cineol on the proliferation of human cell lines HeLa and U373, also
used in the present study to investigate the NF-κB-activity in vitro.
Here, 1,8-cineol-treatmentwas shown to impair the proliferation capabil-
ity of U373 and HeLa cells, a matter closely linked to reduced activity of
NF-κB [41,70–73]. Although strongly impaired by 1,8-cineol-treatment,
we observed no total blockade of proliferation, suggesting a link to the
also not totally blocked activity of NF-κB.
5. Conclusion
In summary, this study demonstrates that 1,8-cineol, a natural
component clinically applied as the active ingredient of Soledum®,
reduces the activity of NF-κB in vitro. We propose a novel mode of ac-
tion through an inhibition of nuclear translocation of NF-κB p65 as
well as a decrease in proinﬂammatory NF-κB target gene expression,
suggesting IκBα as well as JNK as potential targets of 1,8-cineol.
The transcription factor NF-κB is well-described to be involved in a
broad variety of inﬂammatory human diseases, including those closely
linked to the airway such as asthma, but also systemic infections like
rheumatoid arthritis or septic shock. Our ﬁndings may therefore broad-
en the range of 1,8-cineol in treating inﬂammatory diseases or improve
its already described beneﬁcial impact on the therapy of chronic sinus-
itis and bronchitis, chronic obstructive pulmonary disease and bronchial
asthma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.07.001.hibits nuclear translocation of NF-κB p65 and NF-κB target gene expression in a IκBα- and
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